Biogen presents 52-week litifilimab data in cutaneous lupus erythematosus
Participants who switched from placebo to litifilimab at Week 24 showed a rapid onset of effect as early as four weeks.
GetSignal Biogen Inc. BIIB
Biogen said on October 2, 2026, that 52-week Phase 2 results from its ongoing AMETHYST study of litifilimab in cutaneous lupus erythematosus showed continued skin improvement through Week 52. Biogen said the results, presented at a European dermatology congress in Vienna, Austria, are the longest dataset reported for litifilimab in the condition.
Key facts
- Study
- AMETHYST Phase 2/3, Phase 2 part (Part A)
- Duration
- 52 weeks
- Presented at
- European Academy of Dermatology and Venereology (EADV) 2026 Congress, Vienna, Austria
Source: The company's release on GlobeNewswire, October 2, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
